MEDTRONIC COMPLETES THE PURCHASE OF QT VASCULAR'S CHOCOLATE® PTA BALLOON CATHETER

Highlights:

- **Medtronic completes the purchase of the Company's non-drug coated Chocolate® PTA balloon catheter**
- **The completion of this purchase validates the value of this internally developed specialty PTA to improve outcomes in patients with peripheral artery disease**

SINGAPORE, 30 January 2018 – QT Vascular Ltd., (the "**Company**" or "**QT Vascular**", and together with its subsidiaries, the "**Group**"), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease. Further to the Company's announcements on 4 September 2017 and 2 November 2017 in relation to the substantial completion of the manufacturing transfer of Chocolate® PTA to a third-party contract manufacturer and the triggering of one of the option triggers set out in the asset purchase option agreement ("**Option Agreement**"), the Board of Directors of the Company is pleased to announce the completion of the sale of Chocolate® PTA balloon catheter to Medtronic. Further details of the Option Agreement can be found in the Company's circular to shareholders dated 18 May 2017.

In February 2017, QT Vascular signed an exclusive, worldwide distribution agreement with Medtronic to distribute the Chocolate PTA balloon catheter. It is currently commercially available by Medtronic in the United States and Europe.

"Through our distribution agreement with QT Vascular, we have seen a lot of excitement from physicians about this unique, specialty balloon," said Mark Pacyna, vice president and general manager of the Peripheral business in the Medtronic Cardiac & Vascular Group. "The acquisition of the Chocolate® PTA balloon will strengthen our portfolio, providing customers with a both a stand-alone and adjunctive treatment option for peripheral artery disease above and below the knee."

Independently, QT Vascular will continue to develop and market its other products including a drug coated version of Chocolate® PTA (Chocolate Touch®), which has received Investigational Device Exemption approval from the U.S. Food and Drug Administration and its coronary products portfolio of both drug and non-drug coated products.

"We are very pleased with the completion of the sale of our non-drug coated peripheral product, the Chocolate® PTA balloon catheter, to Medtronic, the world's leading medical device company," stated Eitan Konstantino, PhD, CEO of QT Vascular. "This is a validation of the intrinsic value of our internally developed products. QT Vascular will continue to focus on achieving milestones related to our coronary and drug coated product portfolio."

~~ End ~~

ABOUT THE CHOCOLATE PTA BALLOON CATHETER

The Chocolate® PTA balloon catheter has a unique nitinol constraining structure that is designed to provide atraumatic dilatation in the treatment of blocked arteries. The Chocolate BAR post-market registry of 490 patients showed that use of Chocolate® PTA resulted in low rates of dissections and bailout stenting. Chocolate® PTA may be used as a stand-alone treatment or adjunctive treatment for stenosis in vessels above and below the knee. It is approved for use in the United States, Europe, Australia, Turkey, Singapore, and Hong Kong. Currently, it is commercially available by Medtronic in the United States and Europe.

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

For more information, please visit the Company's website at www.qtvascular.com

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company does not undertake any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).